Literature DB >> 20827746

Probing multidrug-resistance and protein-ligand interactions with oxatricyclic designed ligands in HIV-1 protease inhibitors.

Arun K Ghosh1, Chun-Xiao Xu, Kalapala Venkateswara Rao, Abigail Baldridge, Johnson Agniswamy, Yuan-Fang Wang, Irene T Weber, Manabu Aoki, Salcedo Gomez Pedro Miguel, Masayuki Amano, Hiroaki Mitsuya.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20827746      PMCID： PMC3523686          DOI： 10.1002/cmdc.201000318

Source DB:  PubMed          Journal:  ChemMedChem        ISSN： 1860-7179            Impact factor:   3.466


× No keyword cloud information.
  25 in total

1.  JE-2147: a dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1.

Authors:  K Yoshimura; R Kato; K Yusa; M F Kavlick; V Maroun; A Nguyen; T Mimoto; T Ueno; M Shintani; J Falloon; H Masur; H Hayashi; J Erickson; H Mitsuya
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

2.  Atomic resolution crystal structures of HIV-1 protease and mutants V82A and I84V with saquinavir.

Authors:  Yunfeng Tie; Andrey Y Kovalevsky; Peter Boross; Yuan-Fang Wang; Arun K Ghosh; Jozsef Tozser; Robert W Harrison; Irene T Weber
Journal:  Proteins       Date:  2007-04-01

Review 3.  Bis-tetrahydrofuran: a privileged ligand for darunavir and a new generation of hiv protease inhibitors that combat drug resistance.

Authors:  Arun K Ghosh; Perali Ramu Sridhar; Nagaswamy Kumaragurubaran; Yasuhiro Koh; Irene T Weber; Hiroaki Mitsuya
Journal:  ChemMedChem       Date:  2006-09       Impact factor: 3.466

4.  Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization.

Authors:  Yasuhiro Koh; Shintaro Matsumi; Debananda Das; Masayuki Amano; David A Davis; Jianfeng Li; Sofiya Leschenko; Abigail Baldridge; Tatsuo Shioda; Robert Yarchoan; Arun K Ghosh; Hiroaki Mitsuya
Journal:  J Biol Chem       Date:  2007-07-17       Impact factor: 5.157

Review 5.  Why do patients fail HIV therapy?

Authors:  L Waters; M Nelson
Journal:  Int J Clin Pract       Date:  2007-06       Impact factor: 2.503

6.  Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere.

Authors:  A K Ghosh; J F Kincaid; W Cho; D E Walters; K Krishnan; K A Hussain; Y Koo; H Cho; C Rudall; L Holland; J Buthod
Journal:  Bioorg Med Chem Lett       Date:  1998-03-17       Impact factor: 2.823

7.  Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.

Authors:  Arun K Ghosh; Perali Ramu Sridhar; Sofiya Leshchenko; Azhar K Hussain; Jianfeng Li; Andrey Yu Kovalevsky; D Eric Walters; Joseph E Wedekind; Valerie Grum-Tokars; Debananda Das; Yasuhiro Koh; Kenji Maeda; Hiroyuki Gatanaga; Irene T Weber; Hiroaki Mitsuya
Journal:  J Med Chem       Date:  2006-08-24       Impact factor: 7.446

8.  Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M.

Authors:  Andrey Yu Kovalevsky; Yunfeng Tie; Fengling Liu; Peter I Boross; Yuan-Fang Wang; Sofiya Leshchenko; Arun K Ghosh; Robert W Harrison; Irene T Weber
Journal:  J Med Chem       Date:  2006-02-23       Impact factor: 7.446

Review 9.  Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.

Authors:  Arun K Ghosh; Bruno D Chapsal; Irene T Weber; Hiroaki Mitsuya
Journal:  Acc Chem Res       Date:  2007-08-28       Impact factor: 22.384

10.  The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy.

Authors:  Deenan Pillay; Krishnan Bhaskaran; Suzanne Jurriaans; Maria Prins; Bernard Masquelier; Francois Dabis; Robert Gifford; Claus Nielsen; Court Pedersen; Claudia Balotta; Giovanni Rezza; Marta Ortiz; Carmen de Mendoza; Claudia Kücherer; Gabriele Poggensee; John Gill; Kholoud Porter
Journal:  AIDS       Date:  2006-01-02       Impact factor: 4.177
View more
  32 in total

1.  HIV-1 protease with 20 mutations exhibits extreme resistance to clinical inhibitors through coordinated structural rearrangements.

Authors:  Johnson Agniswamy; Chen-Hsiang Shen; Annie Aniana; Jane M Sayer; John M Louis; Irene T Weber
Journal:  Biochemistry       Date:  2012-03-20       Impact factor: 3.162

Review 2.  Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS.

Authors:  Arun K Ghosh; Heather L Osswald; Gary Prato
Journal:  J Med Chem       Date:  2016-01-22       Impact factor: 7.446

Review 3.  Tetrahydrofuran, tetrahydropyran, triazoles and related heterocyclic derivatives as HIV protease inhibitors.

Authors:  Arun K Ghosh; David D Anderson
Journal:  Future Med Chem       Date:  2011-07       Impact factor: 3.808

Review 4.  Highly resistant HIV-1 proteases and strategies for their inhibition.

Authors:  Irene T Weber; Daniel W Kneller; Andres Wong-Sam
Journal:  Future Med Chem       Date:  2015       Impact factor: 3.808

5.  Enantioselective Synthesis of Dioxatriquinane Structural Motifs for HIV-1 Protease Inhibitors Using a Cascade Radical Cyclization.

Authors:  Arun K Ghosh; Chun-Xiao Xu; Heather L Osswald
Journal:  Tetrahedron Lett       Date:  2015-06-03       Impact factor: 2.415

6.  Novel P2 tris-tetrahydrofuran group in antiviral compound 1 (GRL-0519) fills the S2 binding pocket of selected mutants of HIV-1 protease.

Authors:  Hongmei Zhang; Yuan-Fang Wang; Chen-Hsiang Shen; Johnson Agniswamy; Kalapala Venkateswara Rao; Chun-Xiao Xu; Arun K Ghosh; Robert W Harrison; Irene T Weber
Journal:  J Med Chem       Date:  2013-01-23       Impact factor: 7.446

7.  Design, synthesis, biological evaluation and X-ray structural studies of HIV-1 protease inhibitors containing substituted fused-tetrahydropyranyl tetrahydrofuran as P2-ligands.

Authors:  Arun K Ghosh; Cuthbert D Martyr; Luke A Kassekert; Prasanth R Nyalapatla; Melinda Steffey; Johnson Agniswamy; Yuan-Fang Wang; Irene T Weber; Masayuki Amano; Hiroaki Mitsuya
Journal:  Org Biomol Chem       Date:  2015-10-14       Impact factor: 3.876

8.  Design of novel HIV-1 protease inhibitors incorporating isophthalamide-derived P2-P3 ligands: Synthesis, biological evaluation and X-ray structural studies of inhibitor-HIV-1 protease complex.

Authors:  Arun K Ghosh; Margherita Brindisi; Prasanth R Nyalapatla; Jun Takayama; Jean-Rene Ella-Menye; Sofiya Yashchuk; Johnson Agniswamy; Yuan-Fang Wang; Manabu Aoki; Masayuki Amano; Irene T Weber; Hiroaki Mitsuya
Journal:  Bioorg Med Chem       Date:  2017-04-09       Impact factor: 3.641

9.  Extreme multidrug resistant HIV-1 protease with 20 mutations is resistant to novel protease inhibitors with P1'-pyrrolidinone or P2-tris-tetrahydrofuran.

Authors:  Johnson Agniswamy; Chen-Hsiang Shen; Yuan-Fang Wang; Arun K Ghosh; Kalapala Venkateswara Rao; Chun-Xiao Xu; Jane M Sayer; John M Louis; Irene T Weber
Journal:  J Med Chem       Date:  2013-05-01       Impact factor: 7.446

10.  Design and Synthesis of Highly Potent HIV-1 Protease Inhibitors Containing Tricyclic Fused Ring Systems as Novel P2 Ligands: Structure-Activity Studies, Biological and X-ray Structural Analysis.

Authors:  Arun K Ghosh; Prasanth R Nyalapatla; Satish Kovela; Kalapala Venkateswara Rao; Margherita Brindisi; Heather L Osswald; Masayuki Amano; Manabu Aoki; Johnson Agniswamy; Yuan-Fang Wang; Irene T Weber; Hiroaki Mitsuya
Journal:  J Med Chem       Date:  2018-05-15       Impact factor: 7.446
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.